Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fox, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fox, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: permissions@oupjournals.org

Future perspectives of If inhibition in various cardiac conditions

Kim Fox*

Director of Cardiology, Royal Brompton & National Heart and Lung Hospital, Sydney Street, London SW3 6NP, England

* Corresponding author. Tel: (44) 207 351 86 26; fax: (44) 207 351 86 29. E-mail address: d.curcher{at}rbh.nthames.nhs.uk

Heart rate (HR) is a major determinant of myocardial oxygen consumption and myocardial perfusion in patients with ischaemic heart disease. Large epidemiological studies have demonstrated that high resting HR is a strong predictor of total and cardiovascular mortality in the healthy population and in patients with hypertension, in patients with metabolic syndromes, in the elderly, and in patients with coronary artery disease (CAD). HR modulation with beta-blockers has shown favourable effects on post-myocardial infarction mortality in correlation with their HR-lowering actions. In this regard, because of their pharmacological action, inhibitors of the sinus pacemaker If current, agents that exclusively reduce HR, may be of particular importance as antianginal agents, and have potential utility in reducing morbidity and mortality in cardiovascular disorders in patients with CAD and in patients with heart failure. Sinus tachyarrhythmias are a heterogeneous group of disorders that are often difficult to manage. A pure HR reduction may be a novel way of treatment for these patients.

Key Words: Heart rate • Ivabradine • Coronary artery disease • Congestive heart failure • If inhibition • Sinus node inhibitor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
M. Tendera
Editorial: If inhibition: from pure heart reduction to treatment of stable angina
Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H3 - H6.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.